Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


USANA plans China inroads

This article was originally published in The Tan Sheet

Executive Summary

USANA Health Sciences begins offering its nutritional and personal-care products in China - a "significant growth opportunity," the firm announced May 24 at its Asia Pacific convention in Hong Kong. Asia Pacific countries already drive the bulk of the Salt Lake City-based direct-seller's sales growth; net sales in the region increased 41.5 percent to $58.6 million in USANA's first quarter (1"The Tan Sheet" May 3, 2010). The firm said May 21 it will introduce to Asia Pacific USANA Calming Tea with L-theanine and Sense Blanc Balance Serum and Moisture Masq

You may also be interested in...

Sales & Earnings In Brief

Sanofi seeks more acquisitions: Sanofi-Aventis continues to "hunt" for bolt-on acquisitions to further diversify its portfolio and feed its pipeline now that it has "properly bedded down and integrated" Chattem, said CEO Chris Viehbacher. He told analysts April 29 that the environment is "quite promising" for acquisitions and Sanofi is "aggressively pursuing external growth opportunities." The Chattem deal significantly boosted Sanofi's consumer health care business, which grew 42.5 percent to €499 million ($661.1 million) in the firm's fiscal 2010 first quarter, according to a same-day release (1"The Tan Sheet" March 15, 2010). Viehbacher lauded Chattem as a keystone in the company's future as a switch platform for the allergy medication Allegra. He noted Sanofi filed the paperwork with FDA for the switch in March; he expects the switch evaluation to take the same amount of time as other new product applications. Prescription sales for Allegra fell 27.1 percent in the quarter due to new competition from generics launched in the U.S. last November. Overall sales for the Paris-based firm grew 5.8 percent, according to the release

Long Hot Summer For Novel Drug Reviews Forecast At US FDA

Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.

Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza

The latest drug development news and highlights from our US FDA Performance Tracker.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts